SmithKline defends its new diabetes drug
Thursday 02 September 1999
"We have sent a letter to a small group of fairly technical doctors basically saying there's misinformation around," said a spokeswoman for the company. "We send letters to doctors all the time keeping them informed about our products."
The company declined to give details of the letter, said to cite a case in which a patient taking Avandia died of liver failure.
The spokeswoman said: "Rumours of this nature began circulating in the US prior to the launch of Avandia. We have received no reports of deaths which we believe are attributable to Avandia."
Analysts dismissed the notion Avandia was to blame for the alleged fatality. One said: "There's no reason to suppose it wasn't because of factors isolated from Avandia."
The market for type II diabetes treatments is becoming more competitive. Avandia is a replacement for US-based Warner-Lambert's drug Rezulin, whose application was limited after it was linked to liver toxicity in around one in 50,000 patients.
Since its launch in June, there have been 215,000 Avandia prescriptions. New prescriptions last week topped 6,000 and are expected to overtake Rezulin within weeks. Actos, a rival manufactured by Eli Lilly, the US pharmaceuticals group, came to the market in July. Its prescriptions in its fourth week were just 500. Lehman Brothers expects Avandia and Actos to have sales of $1.8bn and $2bn respectively in 2004/5.
SmithKline shares closed down 21.5p at 789p yesterday, having earlier fallen to 767p. Rumours swept the market that the US Food and Drug Association was preparing a note to doctors about Avandia. SmithKline said there had been no "dear doctor" letter from the FDA.
peopleContenders for Time magazine's Person of the Year are a mixture of the good, the bad and the holy
newsAs the world remembers Mandela the hero, the prison where he spent 27 years seems all the more brutal
tvSteven Moffat reveals the actor was dying to take on the role of the Time Lord and says he is excited to see what he will do with the character
sportBayern Munich 2 Manchester City 3: City come from two down to beat reigning European Champions
arts + ents... and a chance to paint Booker Prize winning author Hilary Mantel
danceUnder Tamara Rojo's inspired direction, it seems possible that it could challenge the dominance of the Royal Ballet. We meet some established names and rising stars
travelDiscover Uruguay's jet-set beach resort, an Atlantic enclave with plenty of art and culture to explore on the side
The ten coldest places on Earth
Sir Ian McKellen hits back at Damian Lewis' 'fruity actor' claims
Uruguay becomes first country to legalise marijuana trade
Kenyan politician Mike Sonko left red-faced after photoshopping himself next to Nelson Mandela
Nelson Mandela memorial: Cheers, jeers and a masterclass from Barack Obama that stole the show
- 1 Mountain goats' miraculous escape from avalanche captured in dramatic video footage
- 2 It’s shameful that our universities have accepted gender segregation under pressure from the most oppressive religious fanatics
- 3 Sir Ian McKellen hits back at Damian Lewis' 'fruity actor' claims
- 4 Kenyan politician Mike Sonko left red-faced after photoshopping himself next to Nelson Mandela
- 5 Selfie at funeral: Cameron squeezes in on Obama snap at Mandela memorial
- < Previous
- Next >
iJobs Money & Business
£45000 - £55000 per annum + Training and Benefits : Harrington Starr: A leadin...
£59999 - £80001 per annum + Benefits: Pro-Recruitment Group: Senior Manager in...
attractive: Citifocus: Highly prestigious Investment Management house based in...
£70000 - £90000 per annum + benefits + bonus: Pro-Recruitment Group: Our leadi...